Corvus Pharmaceuticals, Inc.
CRVS
$4.50
-$0.13-2.81%
| 09/30/2024 | 06/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 11.64% | -16.39% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 22.24% | -5.09% | |||
| Operating Income | -22.24% | 5.09% | |||
| Income Before Tax | -843.62% | 25.24% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -843.62% | 25.24% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -843.62% | 25.24% | |||
| EBIT | -22.24% | 5.09% | |||
| EBITDA | -22.32% | 5.07% | |||
| EPS Basic | -744.40% | 38.61% | |||
| Normalized Basic EPS | -744.84% | 38.65% | |||
| EPS Diluted | -744.40% | 38.61% | |||
| Normalized Diluted EPS | -744.84% | 38.65% | |||
| Average Basic Shares Outstanding | 11.71% | 21.76% | |||
| Average Diluted Shares Outstanding | 11.71% | 21.76% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||
